Drugs in R & D

, Volume 6, Issue 4, pp 249–252 | Cite as


CGP 33101, E 2080, RUF 331, Xilep
Adis R&D Profile


Placebo Recipient Adjunctive Therapy Partial Seizure Seizure Frequency Rufinamide 


  1. 1.
    Eisai Co Ltd. Eisai Announces In-Licensing Agreement with Novartis for Rufinamide, A New Antiepileptic Agent. Media Release: 9 Feb 2004. Available from URL: http://www.eisai.com Google Scholar
  2. 2.
    Eisai Co Ltd. Eisai Announces Submission of Marketing Authorization Application of the Anti-epileptic Agent Inovelon in Europe. Media Release: 30 Mar 2005. Available from URL: http://www.eisai.co.jp Google Scholar
  3. 3.
    Cheung WK, Kianifard F, Wong A, et al. Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension. Pharmaceutical Research 12: 1878–1882, Dec 1995PubMedCrossRefGoogle Scholar
  4. 4.
    Waldmeier F, Gschwind H-P, Rouan M-C. Metabolism of the new anticonvulsive trial drug rufinamide (CGP 33101) in healthy male volunteers. Epilepsia 37 (Suppl. 5): 167, 1996Google Scholar
  5. 5.
    Pålhagen S, Canger R, Henriksen O, et al. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Research 43: 115–124, Feb 2001PubMedCrossRefGoogle Scholar
  6. 6.
    Chang S-W, Choi L, Karoplchyk MA. A pharmacokinetic evaluation of rufinamide in elderly and younger subjects. Epilepsia 39 (Suppl. 6): 59, 1998Google Scholar
  7. 7.
    Sachdeo RC, Rosenfeld WE, Choi L. Pharmacokinetics and safety of adjunctive rufinamide therapy in pediatric patients with epilepsy. Epilepsia 39 (Suppl. 6): 166–167, 1998Google Scholar
  8. 8.
    Litzinger MJ, Hanny A. Safety and efficacy of open-label rufinamide as adjunctive therapy in pediatric patients with partial seizures. Epilepsia 40 (Suppl. 7): 114 (plus poster), 1999Google Scholar
  9. 9.
    Vazquez BR, Sachedo R, Maxoutova AL, et al. Efficacy and safety of rufinamide as adjunctive therapy in adult patients with therapy-resistant partial-onset seizures. Epilepsia 41 (Suppl. 7): 255, 2000Google Scholar
  10. 10.
    Kapeghian JC, Madan A, Parkinson A. Evaluation of rufinamide (CGP 33101), a novel anticonvulsant, for potential drug interactions in vitro. Epilepsia 37 (Suppl. 5): 26, 1996Google Scholar
  11. 11.
    Svendsen KD, Choid L, Chen B-L. Single-center, open-label, multiple-dose pharmacokinetic trial investigating the effect of rufinamide administration on Ortho-Novum 1/35 in healthy women. Epilepsia 39 (Suppl. 6): 59, 1998Google Scholar

Copyright information

© Adis Data Information BV 2005

Personalised recommendations